Completed Equality Screenings - Quarter 1 - April 2013 - June 2013
Date published:
In fulfilling the commitments within its Equality Scheme the Department equality screens policies to assess the impact and determine if a full Equality Impact Assessment (EQIA) is required.
Documents
- General Ophthalmic Services Determination 2009
- NICE Clinical Guidelines – CG157 Hyperphosphataemia in chronic kidney disease
- NICE Clinical Guideline CG158 - Conduct disorders in children and young people
- NICE Technology Appraisals (TA 274 - Ranibizumab for treating diabetic macular oedema (rapid review of technology appraisal guidance 237)
- NICE Technology Appraisals - TA 275 - Apixaban for the prevention of stroke and systemic embolism in people with non-valvular atrial fibrillation
- NICE Technology Appraisals:- TA 276- Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin
- NICE Technology Appraisal TA278 - Omalizumab for the treatment of severe persistent allergic asthma in children aged 6 and over and adults (review of TA133 and TA201)
- NICE Technology Appraisal TA279 - Percutaneous vertebroplasty and percutaneous balloon kyphoplasty for the treatment of osteoporotic vertebral fractures
- NICE Technology Appraisal TA280 - Abatacept for the treatment of rheumatoid arthritis only after the failure of conventional disease-modifying anti-rheumatic drugs (rapid review of TA234)
- NICE Technology Appraisal TA282 - Pirfenidone for treating idiopathic pulmonary fibrosis
- Optical Charges and Payments (Amendment) Regulations (Northern Ireland) 2013
- Breastfeeding - A Great Start: A Strategy for Northern Ireland 2013-2023